YOLFTbeta
Zhejiang Cheng Yi Pharmaceutical Co Ltd

Zhejiang Cheng Yi Pharmaceutical Co Ltd

603811 · SHG · Healthcare / Drug Manufacturers - Specialty & Generic

6.52CNY-0.02 (-0.31%)

Price History

Full chart

Market Stats

Previous Close6.54
Open6.54
Day Range6.49 – 6.60
52-Week Range6.61 – 13.56
Volume2.90M
Market Cap3.20B
P/E (TTM)17.48
Forward P/E0.00
EPS0.40
Dividend Yield4.29%
Beta0.07
50-Day Avg7.18
200-Day Avg7.88

About

Zhejiang Cheng Yi Pharmaceutical Co., Ltd. engages in the research, development, production, and sales of formulations and active pharmaceutical ingredients in China and internationally. The company offers glucosamine hydrochloride raw materials and preparations, gastrodin raw materials, ribavirin preparations raw materials, and sulfur dioxide raw materials. It also provides injections, food, capsules, tablets, traditional Chinese medicines, preparations, and intermediates; and joint-related drugs, diuretics and antihypertensive drugs, antiviral drugs, antitumor drugs, vitamins, and sedative and brain-boosting drugs, as well as other health products and medical instruments. The company was formerly known as Wenzhou No. 3 Pharmaceutical Factory and changed its name to Zhejiang Cheng Yi Pharmaceutical Co., Ltd. in April 2001. Zhejiang Cheng Yi Pharmaceutical Co., Ltd. was founded in 1966 and is based in Shanghai, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Chunjian Zhao
  • Employees604
  • HeadquartersBuilding 20, Shenhong Road, Shanghai, China, 201100, China
  • Websitehttps://www.chengyipharma.com

Leadership

  • Mr. Chunjian ZhaoGM & Director · b. 1977
  • Mr. Sun Zhan LuChief Financial Officer · b. 1978
  • Ms. Ze Hui KeDeputy GM, Secretary of the Board & Director · b. 1986
  • Mr. Zhi Hong ZhangDeputy GM & Director · b. 1969
  • Hai Ping XuAccounting Supervisor
  • Ms. Lina YanVice President of Sales · b. 1978
  • Mr. Zhi Dong LuDeputy General Manager · b. 1974

Financials

Income Statement

Currency: CNY2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue215.28M255.43M266.06M320.23M316.95M321.22M340.89M545.77M681.23M758.13M693.96M654.97M671.63M714.37M812.35M
Growth (%)-+18.65%+4.16%+20.36%-1.02%+1.35%+6.12%+60.10%+24.82%+11.29%-8.46%-5.62%+2.54%+6.36%+13.72%
Cost of Revenue138.32M152.06M150.42M163.42M154.24M160.99M167.90M197.13M188.34M206.41M208.98M217.80M248.45M225.17M245.34M
Gross Profit76.96M103.38M115.64M156.81M162.71M160.24M173.00M348.64M492.89M551.72M484.99M437.17M423.17M489.20M567.01M
Gross Margin35.75%40.47%43.46%48.97%51.34%49.88%50.75%63.88%72.35%72.77%69.89%66.75%63.01%68.48%69.80%
Operating Expense62.29M64.55M74.81M93.58M98.17M84.23M94.17M235.93M338.60M361.36M286.45M272.74M249.26M267.99M381.47M
Operating Income14.67M38.82M40.82M63.23M64.54M76.00M78.83M112.71M154.29M190.36M198.54M164.43M173.91M221.21M185.55M
Operating Margin6.81%15.20%15.34%19.74%20.36%23.66%23.12%20.65%22.65%25.11%28.61%25.10%25.89%30.97%22.84%
EBITDA30.84M46.27M58.40M83.95M85.81M95.56M98.55M132.88M175.63M241.81M257.58M234.64M266.71M323.86M322.38M
EBITDA Margin14.33%18.12%21.95%26.22%27.07%29.75%28.91%24.35%25.78%31.90%37.12%35.82%39.71%45.33%39.68%
Net Income13.35M29.30M36.50M53.85M57.71M68.17M69.24M96.91M131.39M165.14M170.80M161.58M162.90M200.70M195.12M
Net Income Margin6.20%11.47%13.72%16.82%18.21%21.22%20.31%17.76%19.29%21.78%24.61%24.67%24.25%28.09%24.02%
R&D-9.17M11.13M10.83M15.91M15.17M13.13M26.26M29.57M31.79M39.72M44.30M47.14M47.08M44.44M
R&D as % of Total Revenue-3.59%4.18%3.38%5.02%4.72%3.85%4.81%4.34%4.19%5.72%6.76%7.02%6.59%5.47%
Interest Expense8.39M-2.49M3.24M1.86M837.00K148.62K731.48K565.87K5.05M5.41M9.24M15.33M11.16M3.83M
Interest Expense % of Total Revenue3.90%-0.93%1.01%0.59%0.26%0.04%0.13%0.08%0.67%0.78%1.41%2.28%1.56%0.47%

Balance Sheet

Currency: CNY2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets295.68M358.12M333.83M329.72M346.13M364.27M672.98M815.99M980.25M1.21B1.32B1.72B1.89B1.73B1.70B
Total Liabilities193.09M179.99M132.43M82.77M86.21M84.11M73.41M142.45M211.29M320.79M323.62M628.16M696.15M463.31M304.55M
Total Equity102.60M178.13M201.40M246.95M259.92M280.17M599.57M660.79M756.62M873.95M986.31M1.09B1.19B1.26B1.39B
Cash36.00M87.36M45.34M37.81M64.11M78.22M73.71M177.94M141.09M72.31M83.32M213.51M294.14M173.04M220.70M
Total Debt101.29M94.35M71.50M21.00M25.00M12.00M-12.63M10.01M120.14M148.54M426.80M443.84M190.41M-
Net Debt65.29M6.99M26.16M-16.81M-39.11M-66.22M-73.71M-165.31M-131.08M47.83M65.22M213.30M149.70M17.37M-

Cash Flow

Currency: CNY2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow10.04M37.96M48.19M84.11M81.94M95.08M66.75M134.30M181.01M177.81M143.49M165.94M194.78M205.72M280.39M
Investing Cash Flow-10.46M-15.40M-30.25M-21.52M-13.10M-19.25M-304.91M6.70M-181.54M-301.91M-101.14M-241.38M-59.60M26.18M-
Financing Cash Flow18.12M28.60M-57.75M-70.12M-44.05M-60.19M233.91M-43.60M-30.71M56.78M-32.67M207.25M-55.38M-355.98M-
Capital Expenditure13.78M18.05M23.57M25.01M16.79M21.63M37.99M271.52M183.81M143.67M134.11M252.85M70.85M59.89M45.40M
Free Cash Flow-3.74M19.91M24.62M59.10M65.15M73.45M28.76M-137.22M-2.80M34.13M9.38M-86.92M123.93M145.83M234.99M
Dividends Paid11.89M14.21M37.10M19.62M46.55M48.69M35.35M35.90M35.78M47.71M58.45M58.45M73.95M76.70M83.48M
FCF to OCF-37.26%52.44%51.09%70.26%79.51%77.25%43.08%-102.18%-1.55%19.20%6.54%-52.38%63.62%70.89%83.81%
Dividend Paid to FCF-317.89%71.40%150.73%33.20%71.44%66.30%122.93%-26.16%-1278.89%139.79%623.21%-67.25%59.67%52.59%35.52%

Earnings

Report DateApr 27, 2017Aug 18, 2017Oct 26, 2017Dec 31, 2017Apr 3, 2018Aug 24, 2018Oct 26, 2018Dec 31, 2018Apr 9, 2019Aug 21, 2019Oct 28, 2019Dec 31, 2019Apr 27, 2020Aug 19, 2020Oct 28, 2020Dec 31, 2020Apr 22, 2021Aug 19, 2021Oct 29, 2021Dec 31, 2021Apr 25, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Apr 25, 2023
EPS Estimate-------------------------
EPS Actual0.220.210.180.070.290.320.310.080.220.370.260.100.210.230.170.190.270.140.180.160.220.110.110.180.17
Surprise-------------------------
Timing------------Pre-marketAfter-hoursPre-market-Pre-marketPre-marketAfter-hours-Pre-market---Pre-market

Key Statistics & Ratios

Market Cap3.20B
Enterprise Value3.09B
Trailing P/E17.48
Forward P/E0.00
Price / Sales3.87
Price / Book2.25
EPS0.40
Book Value3.19
Revenue (TTM)827.47M
Gross Profit (TTM)575.52M
EBITDA251.79M
Profit Margin21.46%
Operating Margin23.19%
Return on Equity13.19%
Return on Assets5.76%
Shares Outstanding458.23M
Shares Float250.43M
Beta0.07
Dividend Yield4.29%
Dividend Rate0.30
Payout Ratio75.81%

Dividends

20231×
0.25Jun 8, 2023
20221×
0.18Jun 17, 2022
20211×
0.25Jun 4, 2021
20201×
0.20Jun 3, 2020
20191×
0.11May 24, 2019
20181×
0.11May 11, 2018
20171×
0.11May 26, 2017

Stock Splits

  • Jun 8, 20237:5
  • Jun 4, 20217:5
  • Jun 3, 20207:5
  • Nov 26, 20187:5